Abstract: Postmenopausal osteoporosis is a disease associated with increased morbidity and mortality. Oral bisphosphonates administered once weekly are associated with adverse events from the upper gastrointestinal system, leading to poor adherence. Zoledronic acid is a nitrogen-containing third-generation bisphosphonate approved for the treatment of postmenopausal osteoporosis. It is a potent antiresorptiveagentwhichexpresseshighaffinityforthehydroxyapatiteoftheboneandaccumulatesatsitesofincreasedboneturnover. Adverseeventsincludefever,flu-likesymptoms,myalgia,arthralgia,andheadache,whilerareadverseeffectsincludehypocalcemia, renal dysfunction, atrial fibrillation, and osteonecrosis of the jaw. The drug is excreted intact through kidneys. Until recently, the recommended dosage was 5 mg given as an annual intravenous infusion. In 2009, intravenous zoledronic acid 5 mg was approved for thetreatmentofpostmenopausalosteoporosisasasingleinfusioneverytwoyears.Thisreviewsummarizesallevidencesupportingthe efficacyofasinglebiennial5mgdoseagainstpostmenopausalosteoporosis.TheFDAapprovalwasbasedonaclinicalrandomizedtrial whichincludedosteopenicpostmenopausalwomenandshowedthatBMDinallmeasuredsitesremainedincreased24monthsafterthe infusion.ManystudiesshowedsimilarresultsconcerningBMDandalsodemonstratedthatboneturnovermarkersremainedsuppressed for 12months.Thelessfrequentadministrationofzoledronicacidisexpectedtoimproveadherenceanddecreasetheadverseevents, leadingsubsequentlytoimprovedclinicalresults.
Introduction
Osteoporosis is a progressive bone disease that associates with increased morbidity and mortality. Bone massalongwithbonequalityarecompromisedleading to decreased bone strength and eventually to increased fracture risk. 1 The fracture risk increases 1.5-to 3-foldasbonemineraldensity(BMD)decreasesby 1standarddeviation(SD).
2 Thestandardmethodto screen for osteoporosis is dual-energy X-ray absorptiometry(DXA),whichmeasuresBMD.LowBMDis consideredariskfactorforfractures.Therefore,DXA should be considered in women 65 and men 70 regardless of risk factors and in younger postmenopausal women and men aged 50-69 years who have clinical risk factors. Additionally, women at menopausaltransitionshouldalsobeexaminedwithDXA in the presence of certain risk factors such as low body weight, previous fracture or the intake of medications whichaffectbonemass.DXAismandatorywhenan individual is a candidate for osteoporosis treatment andformonitoringtreatmentefficacy.Followingthe discontinuation of estrogen therapy, postmenopausal womenshouldalsobeevaluatedwithDXA. 3 According to the World Health Organization (WHO), the diagnosis of osteoporosis is based on the measurement of bone mineral density (BMD) usingtheT-score.TheT-scorerepresentsthenumber of standard deviations from the peak bone mass in healthyyoungadultsofthesamesexandage.Therefore,osteoporosisisdefinedasT-score2.5 standard deviations below the adult mean value. Osteopenia is definedbyaT-scorebetween−1 and −2.5SD. 4 Many risk factors contribute to the development of osteoporosis. Peak bone mass is achieved by the age of 25-30 and is followed by a gradual bone loss which is genetically determined and is around 1% annually. Beyond the genetic component, lifestyle is of great importance. Malnutrition including low intakeofcalciumandVitaminD,increasedalcohol consumption, smoking as well as the lack of exercise predispose to osteoporosis. Additional risk factors are the use of medications that cause bone loss, e.g. corticosteroids as well as the presence of amenorrhea or early menopause. 2 Postmenopausal women experience a higher annual rate of bone loss (4%), which may lead to a 40% bone mass loss between 40-70years. 5 The prevalence of osteoporosis among women over 65 years old varies between 26%-50%, depending on age. 3 According to Melton et al 6 the lifetime risk of a woman over 50 to experience a fragility fractureis40%,comparedtoamanofthesameagewho has 13% risk. A vertebral fracture increases long term morbidity in women. 2 Hip fractures are also a commonandlife-threateningconsequenceofosteoporosis. It is estimated that 3 months after a hip fracture mortalityincreases2.8-to4-fold.Withinayearonly 30% regain optimal function, while 50% become disabled and 10-20% die. 7 Additionally, if the patient remains bedridden, complications such as urinary tract infections, pneumonia and decubitus ulcers may also occur. 3 Osteoporotic fractures have, therefore, physical, psychological and socio-economic consequences. Formoreaccuratescreening,afractureriskalgorithm (FRAX)isavailableontheinternetwhichcalculates the 10-year probability for sustaining an osteoporotic fracture, based on risk factors such as BMD, age, smoking, alcohol consumption, body mass index, corticosteroid use, history of previous personal or parental fracture and rheumatoid arthritis.
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Thetreatmentofosteoporosisincludespreventive strategies,suchasweight-bearingexercise,adequate protein,calciumandvitaminDintake,aswellascessation of smoking. Antiresorptive therapy, as represented by nitrogen-containing bisphosphonates, is consideredasafirstlinetherapyforthetreatmentof osteoporosis and the reduction of osteoporotic fracture risk.
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The purpose of the present study was to review the safety and efficacy of bisphosphonates for the treatment of postmenopausal osteoporosis, aiming at a more detailed presentation of the intravenous infusion of zoledronic acid. English literature was reviewed from 1992 via pubmed using key words related to osteoporosis definition, prevalence, monitoring and associated complications, with emphasis on postmenopausal osteoporosis. Clinical study results deriving mostly from double-blind, placebo-controlled studies, with clinically relevant endpoints and appropriate study methodology were reviewed. More specifically, the results of five randomized clinical trials in addition to the results of one randomized controlled study which was followed by two consecutive open-label extension studies are presented to support thesafetyandefficacyoftheannualzoledronicacid infusion for the treatment of postmenopausal osteoporosis.ThemostrecentFDAapprovalforthebiennial zoledronic acid infusion was based on a randomized, multi-center, double-blind, placebo-controlled trial. Zoledronicacid'sprolongedefficacyisalsosupported by two other randomized controlled trials, two observational studies and an observational extension of a randomized controlled trial.
Bisphosphonates
Bone is a constantly active tissue. The purpose of itscontinuousremodelingistoadjusttomechanical loading, to repair damages and to maintain the homeostasis of calcium and phosphorus. Bone remodeling is the result of the balanced interplay between osteoclasts (bone-absorbing cells) and osteoblasts (bone formationcells).Osteoclastsdegradeoldboneevery 2-4weeks,creatingaresorptionlacuna.Osteoblasts fill this lacuna with newly synthesized osteoid, the extracellular organic matrix, which is consequently mineralized. This bone formation phase lasts 4-6 months and is followed by a resting phase. 2 Bisphosphonates were introduced to clinical practicealmost20yearsagoandareconsideredfirst-line therapy for osteoporosis. Pharmacologically, the structure is characterized by two phosphorus groups attachedtoacarbonatom(P-C-Pstructure),inadditiontotheR1andR2groupsattachedtothecarbon's two other bonds. This particular structure allows bisphosphonates to remain intact during their interaction with osteoclasts. 9 Additionally, the differences in theR2chaindeterminethebonebindingaffinitiesof each bisphosphonate.
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Depending on the presence of a nitrogen atom, bisphosphonates are classified as non-nitrogencontaining(e.g.clodronate,etidronate)andnitrogencontaining (e.g. alendronate, risedronate, ibandronate, zoledronic acid). Bisphosphonates are bone specific agents that exert their anti-resorptive activity through their strong inhibitory effect on osteoclasts. More specifically,afterbindingonbonesurfaces,bisphosphonates are internalized into the osteoclasts and inhibit bone resorption.
Thenon-nitrogen-containingbisphosphonates,which are considered less potent, accumulate into osteoclasts and are metabolized to toxic nonhydrolyzable ATP analogues leading to cell apoptosis. 11, 12 On the contrary, the more effective nitrogen-containing bisphosphonates interfere with protein prenylation by preventing farsenyl diphosphate synthase. 12 Nitrogen-containing bisphosphonates are characterizedbyaprimary(aledronate)ortertiarynitrogen (ibandronate) or a nitrogen-containing heterocyclic ring(e.g.zoledronicacidandrisedronate).Themost strong inhibitor of farnesyl diphosphate synthase is zoledronic acid, followed by risedronate and ibandronate. 16 Furthertotheirinhibitoryactionontheosteoclasts, bisphosphonates interfere with osteoblastic activity. Bisphosphonates potentiate bone marrow stromal cell proliferation and differentiation thus assisting bone formation. 5 Additionally, they promote the production of osteoprotegerin by the osteoblasts which counteracts RANKL and subsequently suppresses bone resorption. 17 Bisphosphonates establish, thus, a lower balance of bone turnover, analogous tothepremenopausalstate.Thisisindicatedbythe lower levels of bone turnover markers, such as the bonecollagenbreakdownproductsCTX(cross-linked C-telopeptide)andNTX(N-telopeptide). 9, [18] [19] [20] [21] [22] Once weekly administered oral bisphosphonates are alendronate and risedronate. Once monthly administered oral bishposphonates are ibandronate and risedronate. The effect of ibandronate on bone mineral density and markers of bone remodeling is similar to this of daily alendronate and risedronate. 23 The major problem regarding oral bisphosphonates is adherence. This term defines the extent to which patients adapt to treatment recommendations. Additionally, it refers to persistence i.e. the actual time between the initiation and discontinuation of treatment. 24 It is of great concern that, according to the WHO, adherence to medication in chronic diseases reaches only 50%. 25 Regarding osteoporosis, Clinical Medicine Reviews in Women's Health 2010:2 poor adherence has been associated with lower suppression of bone turnover markers, lower benefit with respect to BMD and consequently inadequate protection against fracture.
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Duetotheirhighaffinityforbonetissue,bisphosphonates have no systemic effects. 29, 23 Their main adverse events, however, are from the upper gastrointestinal(GI)system,mainlygastroesopahgealreflux, oesophagitis,gastritisandpepticulcers.Thepatient shall, therefore, stay in an upright position (standing or sitting) for at least 30 minutes after drug intake. Additionally, the strict dosing schedule of the oral bisphosphonatesrepresentsanothermajorreasonfor inadequate compliance. Provided that poor adherence leads to inadequate clinical benefit, simplifyingdosingisapromisingstrategy.Theonceweekly administered bisphosphonates are pharmacologically equivalent to the daily administered ones and have been associated with better adherence. 11, [30] [31] [32] On the other hand, the monthly administered ibandronate has not been clearly associated with better adherence. 33 Upper GI adverse events are similar between ibandronate and alendronate, but flu-like and myoskeletalsymptomsaremorefrequentwithibandronate. 34 Except for the adverse events, oral bisphosphonates are characterized by poor bioavailabilty and it is crucial that the administration takes place on an empty stomach with 8 fluid oz (237 ml) tap water to enhance its absorption. 11, 9 In order to avoid the inconveniences deriving from the use of oral bisphosphonates, new intravenous(IV)therapieshavebeendevelopedthatallow dosing at very long intervals which, hopefully, will improve adherence to therapy. Quarterly IV ibandronate (3 mg ibandronate intravenously every 3months)wasapprovedin2006anditsefficacyand safety were found similar to that of the oral monthly regimen. The most recently approved bisphosphonate for IV administration is zoledronic acid. The primary indications for the use of intravenous zoledronic acid were hypercalcemia and skeletal complications of malignancy. 35, 36 Studies in osteopenic and osteoporotic postmenopausal women, however, have shown that the annual IV use of 5 mg zoledronic acid reduced bone turnover markers more quickly and more intensely compared to 70 mg per week of oral alendronate. 37 Therefore, following the concordant results of many studies, the annual IV zoledronic acid regimen(5mg/year)wasapprovedin2007forusein postmenopausal osteoporosis. 38 
Zoledronic Acid Chemistry
Zoledronic acid belongs to the nitrogen-containing bisphosphonates. It has a phosphorus-carbon-phosphorus corewithahydroxylgroupattachedtotheR1position.
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Regardingitschemicalstructure,theheterocyclicimidazole group attached to the R2 position differentiates zoledronic acid from other bisphosphonates. 40 
Mechanism of action
Zoledronic acid expresses a potent antiresorptive action,whichismediatedthroughitshighaffinityfor mineralized bone and especially for sites of high bone turnover. 41 Zoledronic acid inhibits the proliferation of the osteoclasts and induces their apoptosis.
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Zoledronic acid exerts its actions mainly by inhibitingthe farnesyl pyrophosphate (FPP) synthase, an enzyme involved in the cellular biosynthetic mevalonate pathway. 43 Zoledronic acid is considered the most potent inhibitor of FFP synthase. 44 The direct effect is the inhibition of isoprenoid lipids synthesis, such as FFP and geranylgeranyl diphosphate (GGPP), which are necessary for the GTP-binding protein prenylation in osteoclasts. The loss of prenylated GTP-binding proteins has been associated with inhibition of osteoclast activity and induction of osteoclast apoptosis. 45, 39, 43 According to Benford, 43 the apoptosis of the osteoclasts is possibly attributed to the activation of caspase-3-like proteases along with morphological changes and to the loss of mitochondrial membrane integrity. Furthermore, zoledronic acid may enhance osteoblast differentiation 46 with no interference with bone mineralization. 39 
Pharmacokinetics
Zoledronic acid is administered as 5 mg intravenous solutionduringaperiodofatleast15minutes.The patients must be well hydrated before the intravenous infusion, especially if they receive diuretic drugs. Additionally, they must receive the recommended for postmenopausal osteoporosis daily dosage of calcium (atleast1200mg)andvitaminD(800-1200IU).The medication is not metabolized in humans and almost 40% of the IV dose is excreted intact in the urine. Theremaining60%bindstotheboneduetoitshigh affinity for this tissue. The binding level to plasma proteins is 22%. Immediately after infusion, there is a rapid elimination from the systemic circulation, due to the increased absorption of the drug by the bone, followed by a longer elimination phase with a halflifeof146hours. 47 It is noteworthy that less than 1% of the peak concentration observed at the end of the infusioncanbetraced24hoursaftertheinjection. 48 Thesmallamountsofthedrugdetectedinplasmaseveral days after the infusion represent the drug which is gradually released from the bone during bone turnover. Zoledronic acid has minor or no effect on the cytochromeP450enzymesystemanddoesnotaffect the metabolic clearance of substances metabolized viacytochromeP450. 47 The excretion of zoledronic acid by the kidney is independent of the dose or the infusion time and the drug can be detected in urine in trace amounts even28daysaftertheinfusion.Theaffinityofzoledronic acid for the bone tissue is so potent that the amount of the drug traced in the urine in the first 24-hourrepresentsonlytheoneortwo-thirdsofthe total dose. 47 In the presence of mild or moderate renal impairment (Cl Cr = 50-80 ml/min and Cl Cr = 35-50 ml/min respectively) dose adjustments are not considered necessary. 48 Boonen et al 49 investigating the renal safety of zoledronic acid administered for postmenopausal osteoporosis reported that renal function in the treated women was not affected compared to placebo. However, due to the lack of adequate data, the use of zoledronic acid is not recommended in elderly patients with Cl Cr 30 ml/min. The approval of zoledronic acid for the treatment of postmenopausal osteoporosis was based on the HORIZON PFT (Pivotal Fracture Trial).
38 Thiswasadouble-blind,placebo-controlled, multicenter trial which included 7765 patients (mean age73years)andinvestigatedtheanti-fractureefficacy of a single annual dose of zoledronic acid 5 mg during a 3-year period. Inclusion criteria were lumbar spineT-score −1.5 and at least two mild or moderate existing vertebral fractures or a femoral neck T-score−2.5 with or without evidence of existing vertebral fracture. Zoledronic acid reduced the risk of morphometric vertebral fracture by 70% compared to placebo (3.3% in the zoledronic acid versus 10.9% in the placebo group, P  0.001). The hip fracture ratewas1.4%inthezoledronicacidgroupcompared to 2.5% in the placebo group, representing a 41% relative risk reduction (P = 0.002).Inaddition,nonvertebral fractures, clinical fractures, and clinical vertebral fractures were reduced by 25%, 33%, and 77% respectively (P  0.001forallcomparisons).BMD was also increased in the zoledronic acid group by 6.0%, 6.7% and 5.1% in the total hip, lumbar spine and femoral neck respectively compared to placebo. Nevertheless, it should be taken into account that the HORIZON trial included high risk population, who might have shown higher rates of fracture reduction compared to patients without prevalent fractures.
Aseparateplacebo-controlledtrial,theHORIZON-RFT (Recurrent Fracture Trial), investigated the fracture recurrence and mortality in patients with a history of hip fracture receiving zoledronic acid. 50 Infusion of zoledronic acid occurred within 90 days after surgical repair of the hip fracture.The results indicated a 35% risk reduction for any new clinical fracture in the treated group: 8.6% experienced a new clinical fracture in the zoledronic acid group as compared to 13.9% in the placebo. Additionally, the rates of new clinical vertebral fractures were 1.7% and 3.8% and those of new non-vertebral fractures 7.6% and 10.7% in the zoledronic acid and placebo groupsrespectively.Finally,therateofnewhipfractures was 2.0% in the zoledronic acid group and 3.5% in the placebo group, representing a 30% risk reduction.Regardingtheall-causemortality,therewasa 28% reduction in deaths in the zoledronic acid group (P = 0.01).
Reckeret al 51 evaluated the effects of zoledronic acid on bone remodelling and architecture in a substudy of the HORIZON trial. Bone biopsies of 152 patients receiving intravenous zoledronic acid 5 mg annually showed higher trabecular bone volume (P =0.020),highertrabecularnumbers(P =0.008), decreased trabecular separation (P = 0.011) and a trend toward improvement in connectivity density Clinical Medicine Reviews in Women's Health 2010:2 (P =0.062)inthezoledronicacidgroupcomparedto placebo. Additionally, there was a reduction in bone turnoverduetoreductioninactivationfrequency,in mineralizing surface and in volume referent bone formation rate (P  0.0001). Mineral appositional rate was also improved in the zoledronic acid group. (P = 0.0002)Finally,zoledronicacidwasassociated with normal osteoid formation and mineralization of newlyformedbone.Theaboveresultsstronglysuggest that zoledronic acid reduces bone turnover and preserves bone structure and mass.
McClung et al 52 evaluated the safety and efficacy of zoledronic acid versus oral biphosphonate therapy.This randomized, double-blind, multicenter trial was conducted to assess the safety and efficacy of a single IV dose of zoledronic acid 5 mg in comparison with weekly oral alendronate 70 mg in postmenopausal women with low BMD, who were previously on weekly alendronate for at least 1 year priortorandomization.BMDlevelswerestablefor 12 months following the switch from oral alendronate to zoledronic acid in women with osteoporosis. Bone turnover markers, were reduced from baseline after 3 months, returned to baseline after 6 months, and increased thereafter ranging within the premenopausal levels. On the contrary, mean biomarker levels in the group receiving alendronate remained around baseline levels throughout the study. The aggregate rates of adverse events were similar in both groups. Bone biopsies were also evaluated in this study and the results indicated that zoledronic acid and alendronate decreased excessive remodelling without suppressing it. Additionally, there was no observation of marrowfibrosisandtherewasnoexcessaccumulationofunmineralizedosteoid.Finally,78.7%ofthe patients expressed their preference for the annual infusion.Thestudyresultssuggestedthatpatientscan be safely switched from oral alendronate to IV zoledronic acid 5 mg and maintain the achieved therapeutic effect for at least 12 months.
Annual IV zoledronic acid and weekly alendronate were also compared regarding the onset of their action in a randomized, double-blind, double-dummy, multicentertrialof24weeksduration.
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Thepopulation consisted of postmenopausal women with low BMD (T score −2) and the onset of action was assessed using the reductions in urine N-telopeptide oftypeIcollagen(NTX)atweek1.Zoledronicacid was characterized by a more rapid onset of action as itresultedinasignificantlyhigherreductioninurine NTXatweek1comparedtoalendronate(P  0.0001). Additionally, the zoledronic acid group had significantly lower mean urine NTX values during the 24-weekstudy.Furthermore,zoledronicacidresulted in significantly higher reduction of serum β-CTX (beta-C-telopeptideoftypeIcollagen)levelsthroughoutthestudycomparedtoaledronate.Finally,bonespecificalkalinephosphatasewasreducedinagradual manner in both groups, reaching premenopausal range by week 12. Conclusively, annual IV zoledronic acid 5 mg causes a steeper decrease of a higher magnitude in bone resorption markers compared to oral alendronate 70 mg, while both have a similar effect on bone formation.
Devogelaeretal 53 conducted a 5 year study in order toassesstheefficacyandsafetyofprolongeduseof zoledronicacid4mg.Annualinfusionsofzoledronic acid for 2, 3 or 5 years resulted in not excessively reduced bone turnover. Additionally, it was well tolerated and devoid of safety issues. Bone turnover markers decreased from baseline and remained in the premenopausal reference ranges, while BMD was significantlyincreased.
In May 2009, FDA approved the use of a single IV infusion of zoledronic acid 5 mg every two years in postmenopausal osteoporosis.
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Studies have shown prolonged efficacy of the regimen, beyond 12 months. 55 Thisadvantageisattributedto theextremelyhighaffinityofzoledronicacidtothe hydroxyapatite of the bone tissue. After the accumulation of zoledronic acid on the bone surface, the formation of new bone leads to the internalization of the drug, which nevertheless remains active due to the constant bone remodelling. Therefore, the drug is remobilized and re-localized to the bone surface, maintaining its action for months and years. 56 Adherenceisexpectedtobehigherduetothelessfrequent administration. Additionally, the lower risk of adverse events along with the cost reduction will allow more patients to receive zoledronic acid treatment.
A 50% cost reduction results from the switch to biennial administration of zoledronic acid for postmenopausal osteoporosis compared to annual dosage.Thecost-effectivenessofzoledronicacidiseven more evident when it is compared to oral bisphosphonates administered weekly for the same period. 57 Theeconomicbenefitarisingfromthelessfrequent administration of zoledronic acid is very promising taking that postmenopausal osteoporosis is a chronic diseasewhichrequireslong-termmonitoring. Theapprovalofthebiennialregimenwasbasedon a randomized, double-blind, multicenter study which included 581 osteopenic postmenopausal women over 45 years old in early (5 years) or late (5 years)menopause.TheprimaryendpointwasBMD values after 2 years compared to baseline. Three groupsofpatientswereinvestigated.Inthefirstgroup postmenopausal women received zoledronic acid at baseline and again after one year, while in the second group women received zoledronic acid at baseline and placebo at one year. Finally, in the third group women received placebo both at baseline and at one year.The results showed that zoledronic acid given asasingledoseincreasedBMDatlumbarspineby 6.3%and5.4%intheearlyandlatemenopausegroup respectively after two years compared to placebo (both P  0.001).
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According to Grey et al 58 the antiresorptive effects of a single IV infusion of zoledronic acid remain for at leasttwoyears.Resultsinosteopenicpostmenopausal women concerning both BMD and bone turnover markersarecomparablebetween12and24months. Lumbar spine BMD was higher by 5.7% (95% CI: 4.0−7.4)aftertwoyearsinthezoledronicacidgroup compared to placebo (P  0.0001).Similarly,BMD at proximal femoral was increased by 3.9% (95% CI: 2.2-5.7) in the zoledronic acid group compared to placebo (P  0.0001).Moreover,totalbodyBMD was1.7%(95%CI:0.8-2.5)higherinthezoledronic group (P  0.0001). Bone turnover was assessed by measuring β-CTX and NTX for bone resorption and P1NP and osteocalcin for bone formation. The mean levels of all four markers remained decreased by at least 38% throughout the study (P  0.0001 for each marker). These findings indicate that the antifractureefficacyofzoledronicacidmaypersistuntil 24monthsafterinfusion.
Theprolongedefficacyofasingle5mginfusionof zoledronic acid has been suggested by many studies which investigated osteopenic patients with diseases causing low bone mass, apart from postmenopausal osteoporosis. Bolland et al 59 conducted a study in HIV-infected men with osteopenia and reported that two years after the second of two annual zoledronic acid4mginfusionsBMDincreased,whileboneturnover markers remained decreased. At all time points, bone turnover markers were lower in the zoledronic acid group and the levels of urine N-telopeptide, serum C-telopeptide and osteocalcin did not differ significantly between 12 and 24 months. BMD in all measurement sites increased in the zoledronic acid group and its values did not vary significantly between12and24.Itisnoteworthythatinthisstudy CTXlevelsbetween12and24monthsweresimilar to those of postmenopausal women receiving annual infusions of zoledronic acid 5 mg. 38 Theefficacyofasingleinfusionofzoledronicacid 4mgbeyond12monthswasalsoevaluatedinastudy which included both female and male patients with lowBMD.Themeasurementofboneturnovermarkers at 18 months after the infusion revealed that both CTX-I and BSAP remained decreased compared to baseline values (P = 0.009 and P =0.02respectively). However,serumCTX,whichwasdecreasedby66% at12months,wasonly41%belowbaselinevalueat 18months,reflectingapossiblepartiallossofeffect. On the other hand, bone-specific alkaline phosphatase(BSAP)was31%and27%belowbaselinevalue at 12 and 18 months respectively, compared to baseline.Additionally,BMDwasincreasedat18months compared to 12 months (6.1% in lumbar spine and 2.0%intotalhip).
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According to a study evaluating the efficacy of a4mgsingledoseofzoledronicacidinosteopenic cancer patients, BMD at lumbar spine increased by 3.1%at12months,5.2%at24monthsand5.3%at 36 months compared to baseline values (P 0.001). Additionally, BMD at hip increased by 2.7%, 3.5% and 4.3% at 12, 24 and 36 months respectively (P 0.001).Itisnoteworthythatthreeyearsafterthe infusion increases in BMD compared to baseline at bothspineandhipwereobservedin84%and90%of theparticipants.Additionally,serumNTXdecreased by 42%, 33% and 31% at 12, 24 and 36 months, respectively (P  0.001). Conclusively, zoledronic acid exhibits a prolonged antiresorptive effect on BMD beyond 12 months after a single infusion. 
indications beyond postmenopausal osteoporosis
Thefirstindicationofzoledronicacidwasthetreatment of malignancy-associated hypercalcemia, mainly in patients with prostate cancer, breast cancer, lung cancer or multiple myeloma. 62 Furthermore, zoledronic acid prevents manifestations such as pathological fractures, bone pain and spinal compression so that the need for bone radiation or surgery could be avoided.Specifically,metastaticprostatecancermay be associated with bone loss, which is also enhanced by the androgen deprivation therapy. 63 In these cases, zoledronic acid acts effectively by increasing BMD, 64, 65 by reducing bone turnover markers, 66 while it protects from pathologic fractures and bone pain.
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Therecommendeddosageis4mgintravenously(IV) every3to4weeks.
Regardingbreastcancer,zoledronicacidreduces bone loss and prevents fractures in women receiving estrogen depleting therapies, such as aromatase inhibitors. 67 In addition, monthly IV infusions of zoledronic acidareafirst-linetherapyfortheskeletalmanifestations of multiple myeloma. 68, 69 Hypercalcemia of malignancy(HCM)isencounteredinthefinalstages of malignancies in 5-10% of all cancer patients and is treatedwith4mgintravenousinfusionsofzoledronic acid with a frequency depending on the underlying disease and patient response. 70 Additionally, zoledronic acid is considered crucial for the treatment of Paget's disease, as it maintains bone turnover in the desirable range. 61 Recently,intravenouszoledronicacid5mgadmin-istered once annually has been approved for the prevention and treatment of glucocorticoid-induced osteoporosis. It is indicated for both men and women who initiate or continue systemic glycocorticoid theraryofatleast7.5mgprednisoneperday(orequivalent)andwhomustremainonthisregimenforatleast one year.
54

Contraindications
Zoledronic acid is not recommended in patients who are allergic to the active substance or to any other components of the medication. It should not be prescribed during pregnancy due to the potential damage it may cause to the fetus. Additionally, it is contraindicated in the presence of hypoparathyroidism, malabsorption syndromes and thyroid disorders. Patients with severe renal impairment (CrCl  35ml/min)should not receive zoledronic acid as there is not enough clinical evidence for its safety in such populations. Creatininemonitoringandadequatehydrationisessential in patients receiving diuretics or nephrotoxic drugs. Caution is also needed in aspirin-sensitive patients with asthma, due to reports of bronchoconstriction symptoms after the use of zoledronic acid.
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Drug interactions
Zoledronic acid is excreted intact in the urine and has minorornoeffectonthecytochromeP450enzyme system. 47 Aminoglycosides may decrease serum calcium levels. The simultaneous administration of zoledronic acid, therefore, may lead to severe hypocalcemia. Similarly, zoledronic acid infusion in a patient receiving loop diuretics may lead to low calcium levels. Nephrotoxic drugs, such as nonsteroidal anti-inflammatory drugs, should also be given with cautioninpatientsreceivingzoledronicacid.Finally, in the presence of renal impairment, zoledronic acid may influence the excretion of drugs primarily excreted by the kidneys, such as digoxin.
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Adverse events
Zoledronic acid is considered a safe and well tolerated medication when used for the treatment of postmenopausal osteoporosis. It has been mainly associated with flu-like symptoms, which usually lack severity andresolvewithinseveraldaysaftertheironset.These symptoms include fever (18.1%), myalgia (9.4%), headache(6.5%)andarthralgia(6.8%).Thesemanifestations can be limited with the administration of acetaminophen or ibuprophen shortly after zoledronic acid infusion. The frequency of these symptoms is usuallylowerwithsubsequentinfusions. 48 Regardingtheseriousadverseevents,nosignificant differences were observed between patients receiving zoledronic acid and placebo as documented in the HORIZON pivotal fracture trial with the incidence being 30.1% and 29.2% respectively. 38 All-cause mortalityhadanincidenceof3.4%inthezoledronicacid group and 2.9% in the placebo group. Taking into account that zoledronic acid reduces vertebral and non-vertebral fractures, which are an important cause of disability and mortality among postmenopausal women, the use of zoledronic acid for treatment of postmenopausal osteoporosis is expected to improve survival.
Zoledronic acid has been reported to increase serum creatinine, with some rare reports of acute renal failure. On the 9th and 11th day post-dose in theHORIZONpivotalfracturetrial,therewasasignificantincreaseofserumcreatinine(44µmol/l)in the zoledronic acid group compared to placebo (1.3% and0.4%respectively).However,30dayspost-dose, creatinine levels returned at the pre-infusion levels in more than 85% of the patients, while in the remaining patients creatinine levels had normalized by the next annual follow-up. 38, 11 After3yearsnosignificant differences in the levels of serum creatinine or in creatinine clearance were observed between zoledronic acidgroupandplacebo.Therareeventsofacuterenal dysfunction in the zoledronic acid group occur mainly in patients with creatinine clearance (31 ml/min) at baseline. 48 Similar results were observed in the HORIZON-RFTandtheMcClungtrials. 50, 52 Finally, according to Reid et al 71 no significant renal events were observed after administering different doses of zoledronic acid.
Another serious adverse event associated with zoledronicacidisatrialfibrillation(AF).IntheHORIZON PivotalFractureTrialtherewasastatisticallysignificant higher rate of serious atrial fibrillation (requiring hospitalization or becoming life-threatening) in the zoledronic acid group compared to placebo (1.3% and 0.5%, respectively). 72 However, comparing the ratesofoverallatrialfibrillationincidences(serious plusnonserious)therewasnosignificantlydifference between the zoledronic acid and the placebo group. 38 Itshouldbementioned,however,thatinHORIZON PFT the number of patients with arrhythmia was higher in the zoledronic acid group compared to placebo. Additionally, in most patients who developed AFtheincidentoccurredonemonthaftertheinfusion of zoledronic acid, when the drug is not detected in the circulation.
Concerning the HORIZON RFT, which included older patients, no significant difference of the serious and overall AF events was observed between zoledronic acid group and placebo. 50 The pathophysiologyofzoledronicacid-associatedAFremains uncertain. The electrolyte imbalances that develop after infusion, such as hypocalcemia, hypophosphatemia and hypomagnesemia could be implicated. 73, 74 Up to now, healthcare practitioners are recommended to continue their prescribing as previously and patients receiving zoledronic acid to remain on their medication, as no clear association between bisphosphonates andatrialfibrillation(seriousplusnon-serious)could beestablishedbyFDA.
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Osteonecrosisofthejaw(ONJ)isanotherserious but rare adverse event observed during zoledronic acid treatment. ONJ is defined as the presence of exposed bone in the maxillofacial region which remains unhealed eight weeks after the diagnosis by a specialist. 76 ONJ is associated mostly with intravenous bisphosphonates compared to the oral regimens. 77 RiskfactorsforONJareheadandneck radiotherapy, periodontal disease, dental surgery, edentulous regions and trauma due to poorly fitting dentures.Patientssufferingfrominflammatorydental disease have a seven-fold increased risk to develop ONJ.Incancerpatients,predisposingfactorsarethe underlying malignancy, chemotherapy, corticosteroids and systematic or regional infection. 78 Antiangiogenesis, impaired circulation as well as suppressed osteoclastic activity are considered as possible underlying mechanisms for this disorder. 79, 80 Length of exposure in bisphosphonates is crucial for the incidence of ONJ and caution is required for treatment beyond two years. 81 According to Bamias et al 82 ONJ incidence was 1.5% among cancer patients with bone metastases treated with zoledronic acid for 12 months and7.7%inpatientstreatedfor37to48months.
A retrospective study showed that the incidence of ONJ in cancer patients treated with bisphosphonates intravenously was 1 in 71.5. Patients who developedONJsufferedfrommultiplemyelomaand were receiving monthly infusions. 83 In another study, 252 cancer patients treated with bisphosphonates wereevaluatedprospectivelyfor6years.Theoverall incidence of ONJ was 6.7%, while disease-specific incidence was 9.9% for myeloma, 6.5% for prostate cancer and 2.9% for breast cancer. It should be mentioned, however, that the median number of infusions was35inthepatientswhodevelopedONJcompared with15inpatientswithoutONJ(P  0.001). 82 In the PivotalFractureTrial,among7.736postmenopausal osteoporotic women, only two patients developed ONJ: one patient treated with zoledronic acid and one patient who did not receive any therapy. ONJ resolved after appropriate treatment. 38 Concluding,ONJhas100-foldhigherincidencein cancer patients compared to osteoporotic patients. 11 ThemostimportantriskfactorforONJarethefrequentinfusionsadministeredincancerpatients.The lessfrequentdosageinpatientswithpostmenopausal osteoporosis is considered safe regarding the risk of ONJ. Guidelines concerning bisphosphonateassociatedONJshould,therefore,distinguishbetween osteoporosis and cancer populations. In order to minimizetheriskforONJ,adentalevaluationshouldbe conducted before, during and after treatment.
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Zoledronic acid is also associated with hypocalcemia. Notable decrease in calcium levels (less than 7.5mg/dl)occurredin0.2%ofthepatientstreated with zoledronic acid. 54 Thiselectrolyteimbalanceis usuallyasymptomaticandoccursthefirstdaysafter the infusion. Symptoms may include numbness, tingling sensations, especially in the area around the mouth, muscle spasms and cramps. The hypocalcemia and the resulting secondary hyperparathyroidism can be prevented with Vitamin D and calcium administration starting 2 weeks before the infusion. 72 Additionally, local reactions at the infusion site such as itching, redness and pain have been reported in 0.7% of patients receiving zoledronic acid intravenously. 38 Finally,0.2%ofpatientstreatedwithzole-dronicaciddevelopedocularinflammatoryevents. 38 Conjunctivitisandepiscleritispermitslocaltreatment, whilescleritisanduveitisrequirediscontinuationof the treatment. 
Conclusions
Postmenopausalosteoporosisisamajorhealthproblem with serious social and economical aspects. Approximately 50% of women over 50 years will experience an osteoporotic fracture during their lifetime.
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The annually administered intravenous zoledronic acid 5 mg has created an important alternative in the management of postmenopausal osteoporosis. Clinical trials, however, have shown that zoledronic acid maintainsefficacyeven24monthsaftertheinfusion. Thebiennialadministrationofzoledronicacid5mg in patients with postmenopausal osteoporosis will improve adherence, decrease adverse events and cost, whilemaintaininganti-fractureefficacy.
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